Xeris Biopharma, Inc.

125 articles with Xeris Biopharma, Inc.

• Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

  11/10/2021

  Xeris Biopharma Holdings, Inc. today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021.

• Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

  11/2/2021

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 10, 2021.

• Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

  10/25/2021

  Xeris Biopharma Holdings, Inc. today announced a collaboration agreement with Merck, with an option to license Xeris’ suspension-based formulation technology, XeriJect™

• 

  Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio

  10/25/2021

  Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.

• Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

  10/5/2021

  Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”).

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Xeris Pharmaceuticals, Inc. announced that on October 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/17/2021

  Xeris Pharmaceuticals, Inc. today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021

• Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

  9/14/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris.

• Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

  9/8/2021

  Strongbridge Biopharma plc announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. .

• Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company during the H.C. Wainwright 23rd Annual Global Investment Conference.

• Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)

  9/1/2021

  Xeris Pharmaceuticals, Inc. today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatment of hypothyroidism.

• Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

  8/31/2021

  Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals

• Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma

  8/30/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xeris stockholders vote “FOR” all proposals related to the Company’s transaction with Strongbridge Biopharma plc

• Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia

  8/23/2021

  Xeris Pharmaceuticals, Inc. today announced that its supplemental new drug application (sNDA) of Gvoke® Kit was approved by the Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.

• Xeris Pharmaceuticals Strengthens Its Patent Estate

  8/19/2021

  Xeris Pharmaceuticals, Inc. today announced that it has recently been granted three new patents relating to its formulation technology platforms.

• Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®

  8/13/2021

  Xeris Pharmaceuticals, Inc. today announced the achievement of an important milestone of payor coverage for Gvoke

• Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism

  8/11/2021

  Xeris Pharmaceuticals, Inc. today announced that the Food and Drug Administration (FDA) has allowed the Investigational New Drug Application (IND) for its XeriSol levothyroxine for hypothyroidism to proceed.

• Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights

  8/5/2021

  Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, announced financial results for the second quarter and first six months ended June 30, 2021, and recent highlights.

• Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

  7/29/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Thursday, August 5, 2021.

• Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

  7/29/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (Xeris) today announced in accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the Irish Takeover Rules) that, as of the close of business on July 28, 2021, Xeris' issued share capital, excluding treasury shares, is comprised of 66,497,370 shares of common stock with a par value of $0.0001 per share.